However, University Hospitals scientists believe it may also have the potential to shrink HPV-related cancer tumors."We are ...

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the ...

These ingenious compounds bring together the DNA-damaging power of cisplatin and the immune-activating strength of STING agonist MSA-2. Excitingly, these conjugates exhibit remarkable potential as ...

The reference arm of paciltaxel and cisplatin for the Monk et al. 3 trial was selected on the basis of results from a GOG randomized phase III study, which demonstrated an improvement in objective ...

Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of ...

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy ...

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity ...

An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for ...

The second group received no neoadjuvant therapy prior to surgery, followed by either standard of care radiotherapy with cisplatin (100mg/m 2 IV Q3W for 3 cycles) as adjuvant therapy following ...

An expert discusses how patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical cystectomy face a ...

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

The NOTOXIS trial (ClinicalTrials.gov ID: NCT05628233) evaluates the efficacy of SENS-401 in preventing CIO in adult patients with neoplastic disease, four weeks after completion of cisplatin ...